Key result
Capecitabine linked to severe hypertriglyceridemia of 912 mg/dL, causing lipemia-induced hemolysis.
Why the study?
Capecitabine-induced hypertriglyceridemia and its clinical consequences in patients without prior dyslipidemia are not well characterized.
Capecitabine therapy may induce severe hypertriglyceridemia, which can lead to hemolysis and analytical interference in laboratory tests.
Supports lipid monitoring with capecitabine; single case leaves open incidence and mechanisms.
A 71-year-old man with gallbladder adenocarcinoma and no history of dyslipidemia presented with serum triglyceride level of 912 mg/dL after two months of starting Capecitabine. The lipemia due to elevated triglyceride also led to hemolysis, causing analytical interference to other biochemical tests and complete blood count.
No takes yet. Share an insight, caveat, or question.
Thakral et al. (2022) studied this question. Capecitabine induced severe hypertriglyceridemia (912 mg/dL) after two months in a patient with gallbladder adenocarcinoma, causing lipemia-induced hemolysis and analytical interference.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: